Superworth

Travere Therapeutics price to book ratio TVTX

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
193×
10-year median
4.0×
Against its 10-year history
100th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.5× to 193×
Peer median
9.2×

Travere Therapeutics' price to book ratio is 193× as of Oct 23, 2026.

That is above its ten-year median of 4.0×, higher than on 100% of days in the last ten years.

Over that time it ranged from 1.5× in Nov 2023 to 193× in Oct 2026.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far193×21.6×193×
202548.2×21.8×76.4×
202488.5×2.0×90.2×
20232.4×1.5×34.2×
202213.4×5.0×14.6×
20216.2×2.2×8.2×
20204.6×2.2×4.7×
20192.5×1.7×3.1×
20182.9×2.7×4.4×
20172.7×2.1×3.2×
20162.3×1.5×2.8×
20152.4×2.3×7.5×

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

CompanyPrice to book ratio
TVTXTravere Therapeutics193×
INDVIndivior Pharmaceuticalsn/m
ARQTArcutis Biotherapeutics17.8×
LQDALiquidia19.6×
KNSAKiniksa Pharmaceuticals International9.2×
LGNDLigand Pharmaceuticals6.3×
OGNOrganon3.6×
AMRXAmneal Pharmaceuticals197×
ALKSAlkermes plc.4.0×
NRIXNurix Therapeutics2.9×
TGTXTG Therapeutics13.7×
Peer median9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.